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A B S T R A C T
Background: Gastrointestinal basidiobolomycosis (GIB) is a rare mycosis affecting almost exclusively immuno-
competent subjects.
Methods: We describe a case of GIB caused by Basidiobolus ranarum in a 25-year-old Italian immunocompetent
man resident in Ireland who presented a 2-month history of epigastric pain. Suspecting colon cancer he under-
went a right hemicolectomy subsequently leading to a diagnosis of GIB by means of molecular biology. After
surgery a 9-month therapy with itraconazole was employed with a good outcome. A review of medical literature
regarding GIB cases published in the period 1964–2017 is presented.
Results: One-hundred and two cases of GIB were included in this analysis. The disease was observed predomi-
nantly in male gender (74.5%) and children (41.2%). Abdominal pain was the single most common complaint
(86.3%) followed by fever (40.2%) and evidence of an abdominal mass (30.4%). Peripheral blood eosinophilia
was detected in 85.7% of cases. Most of the patients were diagnosed in Saudi Arabia (37.2%) followed by USA
(21.6%) and Iran (20.6%). Surgery plus antifungal therapy was employed in the majority of patients (77.5%). An
unfavourable outcome was documented globally in 18.6% of patients.
Conclusions: GIB seems to be an emerging intestinal mycosis among immunocompetent patients living in the Mid-
dle East and Arizona.
1. Introduction
Basidiobolus ranarum was initially described in 1886 as a fungus cul-
tured from frogs and two years later cultured from their intestinal con-
tents and excreta [1]. It was first isolated in 1955 from decayed leaves
in the United States and subsequently from soil and decaying vegeta-
tion from throughout the world [2–5]. It is actually classified in the
phylum Entomophthoromycota that includes one of the largest groups
of early-diverging terrestrial fungi previously classified in the phylum
Zygomycota (Table 1) [6,7]. B. ranarum belongs to the class Basid-
iobolomycetes which includes a single order and family and it is a com-
mensal in the gut of amphibians (frogs, toads), fish, reptiles and insec
tivorous bats [7]. B. haptosporus, B. heterosporos and B. meristosporos
have been considered in the past as synonyms of the species B. ranarum
[8]. Human disease caused by Basidiobolus was first described as a skin
and subcutaneous indolent and slowly progressing infection, affecting
the limbs, trunk and buttocks of young males residing in tropical and
subtropical regions [9–11]. The exact mode of transmission of the fun-
gus has not yet been characterised but in the case of subcutaneous dis-
ease, it has been attributed to the more frequent habit (by males) of us-
ing decaying plant leaves as toilet paper after defecating in the open or
otherwise via minor skin trauma and insect bites. However, it remains
puzzling how the fungus is introduced into the host's gastrointestinal
tract, thus resulting in gastrointestinal basidiobolomycosis (GIB). It has
been suggested that ingestion of soil, animal faeces or food contami
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Table 1
Taxonomic classification of Basidiobolus ranarum within Entomophthoromycota phylum.
Taxonomy Previous Actual
Phylum Zygomycota Entomophthoromycota
Class Zygomycetes Basidiobolomycetes
Order Entomophthorales Basidiobolales
Family Basidiobolaceae Basidiobolaceae
Species Basidiobolus B. ranarum; B. haptosporus; B. heterosporus; B.
magnus; B. meristoporus; B. microsporus (plus
undescribed new genera)
nated by either might be responsible, explaining the highest number of
cases observed among children.
The first case of GIB was probably reported in 1964 as an autopsy
diagnosis in a 6-year old children from Nigeria who had also subcuta-
neous lesions [4]. However, Brazilian authors were the first who recog-
nised GIB as a distinct clinical entity affecting immunocompetent indi-
viduals [12].
Although considered an extremely rare disease, GIB seems to be an
emerging fungal infection in Saudi Arabia, Iran, Iraq and Arizona in the
United States of America. We report here a case of GIB observed in a
young immunocompetent Italian patient together with a review of the
literature.
2. Materials and methods
2.1. Definitions
We defined a confirmed case of GIB on the basis of either the
characteristic histopathologic appearance of the fungus in tissue biopsy
or from surgical specimens obtained from gastrointestinal organs (i.e.,
stomach, small intestine, colon, rectum, liver, gallbladder, pancreas) or
the isolation of Basidiobolus ranarum from such specimens or identifica-
tion by molecular methods.
The PubMed and Scopus databases were searched for articles (in
English, French, Spanish languages) published between 1964 and 2017
using the following combination of MESH terms: basidiobolomycosis
AND gastrointestinal; basidiobolomycosis AND abdominal infection; Ba-
sidiobolus ranarum AND gastrointestinal infection; entomophtoromycosis
AND gastrointestinal. Articles were reviewed in detail by 2 of us (M.D.P.
and V.D.C.) to determine whether cases met the inclusion criteria. Addi-
tional cases were identified by reviewing references. Several cases were
reported more than once and duplicates were excluded.
3. Results
3.1. Case report
In March 2013, a 25-year-old Italian male was admitted to a special-
ized oncological institute in Milan, for a suspect bowel neoplasm. He
had a history of epigastric and lower right abdominal pain over the last
two months so he had done on February an US abdomen which showed
a mass in the right lumbar-hypogastric region of 65mm in transverse
diameter with associated retroperitoneal lymph nodes. The patient was
an otherwise healthy man with an unremarkable past medical history;
he was living in Cork, Ireland, working as a cook in a hotel.
Physical examination showed no abnormalities except a palpable
tender mass on the right lower quadrant; on laboratory investigations
white blood cell count was 10.1×10⁠9/L (normal value 4.4–11.3) with
0.99×10⁠9/L eosinophils (normal value 0.04–0.4), hemoglobin level of
15.6g/dL, normal liver function tests, electrolyte levels and creatinine
levels. CT scan of the pelvis and lower abdomen showed diffuse cir-
cumferential wall thickening affecting distal ileal loop and cecum, nar
rowing of lumen and regional lymph node involvement (Fig. 1a).
Colonoscopy was performed, revealing a complete stricture of the as-
cending colon due to an ulcerated mass (Fig. 1b). Biopsies were taken
and histopathology showed granulomatous and necrotizing inflamma-
tion. Because of a clinical profile suggestive of malignancy with colonic
obstruction a right hemicolectomy was done. At the histology exam-
ination there were areas of necrotizing inflammation with marked
eosinophilic infiltrate and foreign body-type giant cell reaction; fungal
hyphae were seen within some of the multinucleated giant cells and a
presumptive diagnosis of intestinal zygomycosis was done by the pathol-
ogist.
The patient was referred to our Infectious diseases ward for fur-
ther evaluation and management. Upon reviewing the pathology mate-
rial, the hyphae had few septa, were highlighted by the PAS and Gro-
cott stains and surrounded by eosinophilic and hyaline material (Splen-
dore-Höeppli phenomenon) (Fig. 2). The identification of the fungus
was established by DNA extraction from formalin-fixed paraffin embed-
ded tissue and panfungal polymerase chain reaction (PCR) amplification
of 18S rRNA. Amplified fragment had 99% identity with Basidiobolus ra-
narum [13] (Fig. 3). Because preoperative diagnosis was presumed to be
malignant, no tissue was sent for culture. Pending molecular typing of
fungus, the patient was started on liposomal amphotericin B at the dose
of 5mg/kg, 4 days later substituted with itraconazole po 200mg BID be-
cause resistance and clinical failure with amphotericin B has been de-
scribed.
Immunological deficiencies were excluded by additional investiga-
tions (lymphocyte subpopulations, HIV, HBV, HCV, immunoglobulins,
C3 and C4, oxidative BURST, T-lymphocyte maturation study and
CD11b expression on neutrophils and monocytes). Complete blood
Fig. 1. Computed tomography scan showing a mass in the ascending colon.
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Fig. 2. (A,B) Histopathologic section of colon showing granumomatous inflammation of the colonic wall with prominent eosinophilic infiltrate with a transversely cut hypha (black arrow)
surrounded by an intensely eosinophilic cuff (Splendore-Hoeppli phenomenon, white arrow) (Hematoxylin-eosin x100 and x400). (C,D) Detailed view of large fungal hypha surrounded
by eosinophilic Splendore-Hoeppli material and numerous eosinophils and polymorphonuclear leucocytes (E&E x 400).
Fig. 3. Panfungal PCR that amplifies the internal transcriber space (ITS) region of the rDNA gene performed on multiple samples (F,B1,C3,A2) of paraffin-embedded tissue specimens
from different areas of the mass. Sequenced amplicons gave a 99% matching with Basidiobolus ranarum (One μg and 100ng, respectively were tested).
count, apart from eosinophilia (12% maximum), was normal as other
laboratory results. US abdomen before discharge showed he-
patosplenomegaly, normal ileal and colic loops without any mass. The
patient was discharged in April with oral itraconazole 200mg BID and
regular follow-up was started.
After 3 months abdominal CT was negative. In January 2014 the
patient repeated US abdomen, showing only splenomegaly, and lab-
oratory tests (white blood cell count 7.4×10⁠9/L with 0.23×10⁠9/L
eosinophils). He received itraconazole 200mg x 2/daily for a total of 9
months; at one year follow up he is in good health without relapse of
the disease.
3.2. Review of the literature
Gastrointestinal basidiobolomycosis (GIB) has been considered an
extremely rare disease with only six cases reported in the literature up
to 1994 [4,12,14–16]. However, starting from 1995 a cluster of cases
of GIB was described from Arizona with 19 patients (89% resident in
Arizona) identified between 1995 and 2009at Mayo Clinic, Scottsdale
(Arizona) [17–20]. Eight of these 19 patients had been described sepa-
rately before being finally reviewed by Vikram et al., in 2012 together
with other 25 cases observed outside the United States [21]. All the de-
tailed published cases (with the exception of 12 cases reported in the
review by Vikram and not singularly described) plus the one observed
by us are summarised in Table 2 [4,12,14–20,22–62]. We noted that a
further 18 pediatric cases of basidiobolomycosis were reported in 2017
but they are not included in the present review because of the lack of
any detailed information regarding single cases [63]. Eleven cases were
reported in a 36-year period (1964–2000; a mean of 0.3 cases/year)
and 78 in the last seventeen years (2001–2017; a mean of 4.6 cases/
year) with a 15.3-fold increase. Overall, we considered for the pur-
pose of our review the forty-four cases previously reviewed by Vikram
et al., in 2012 plus fifty-eight new cases (including our present obser-
vation) described in detail after 2008 [21] (Table 3). A male preva-
lence was observed (76/102, 74.5%) with a 3:1 ratio. All but one pa-
tient were immunocompetent [59]. The median age was 19 years (range
1–81 years) and 42 patients (41.2%) were children (age 1–13 years).
The countries of residence in 79.4% of patients were only three: Saudi
Arabia (37.2%), USA (21.6%) and Iran (20.6%) (Fig. 4). Abdominal
pain (86.3%) was the most common presenting symptom followed by
weight loss (33.3%), abdominal distension (16.7%), vomiting (15.7%)
and diarrhea (13.7%) (Table 3). Fever was reported only in 40.2% of
patients and an abdominal mass was palpable in 30.4% of cases. Pe-
ripheral blood eosinophilia was detected in 85% of patients for whom
this data was available. An initial misdiagnosis was made in 68% of
cases (68/102) with neoplasms and inflammatory bowel disease being
3
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Table 2
Chronological summary of 89 case reports of gastrointestinal basidiobolomycosis.
Patient/Reference
Year observation/
Publication Country Age/sex
Clinical
presentation
Leukocyte/Eosinophils/Splendore-
Hoeppli phenomenon
Organ
involvement Diagnosis Therapy Outcome
1/4 NR/1964 Nigeria 6/M Subcutaneous
lesions (penis,
scrotum, perineum);
bloody diarrhea
NR/NR/NR I; C; R; bladder Post-mortem (histopathology) Colostomy; antibiotics Death
2/12 1977/1979 Brazil 13/M Abdominal pain,
fever, weakness,
anorexia
NR/16%/Yes S; D; L; P; C; BT Post-mortem (histopathology) Laparatomy Death 11
days after
surgery
3/12 NR/1979 Brazil 60/M Abdominal pain NR/NR/Yes S; C Histopathology; culture negative Gastrectomy & hemicolectomy; AmB Cured
4/14 1979/1980 Brazil 4/M Fever, abdominal
pain, sweats,
diarrhea
13,500 μL/26%/Yes S; C Histopathology; culture
(Basidiobolus haptosporus)
Surgery Death 12
days after
surgery
(peritonitis)
5/15 NR/1986 USA 69/M Fever, abdominal
pain, nausea,
constipation,
vomiting, right
lower quadrant
mass
19,500 μL/6%/Yes I; Ce; C Histopathology/culture
(B.haptosporus/ranarum)
Surgery/AmB Death 4
weeks after
laparotomy
6/16 1989/1997 Brazil 19/M Fever, abdominal
mass, weight loss,
sweats
12,600 μL/11%/Yes I; Ce; C: Histopathology Surgery/ NR
7/17 1994/1997 USA 49/F Abdominal and
rectal pain,
constipation
followed by mucus
and bloody diarrhea
23,400 μL/NR)/Yes C; R Histopathology/serology Surgery/Itraconazole (5 months) Alive after
13 months
8/22 1996/1998 Kuwait
(Bangladesh)
30/M Rectal bleeding,
constipation, rectal
mass
18-22,000 μL/NR/NR R Histopathology/Culture
(B.ranarum)/serology
Surgery/AmB (3weeks)+ketoconazole
(1 week)
Lost to
follow-up
9/18 1998/1999 USA 37/F Abdominal pain 26,400 μL/10%/NR S; P Histopathology Surgery/Itraconazole (9.5 months) Cured
10/18 1998/1999 USA 59/M Abdominal pain,
mucus, colonic
obstruction
12,100 μL/6%/NR C Histopathology/Culture
(B.ranarum)
Surgery/Itraconazole Cured
11/19 1997/1999 USA 57/M Abdominal pain,
anorexia, fatigue,
constipation
16,400 μL/8%/Yes S; C; R; ureter Histopathology/Culture
(B.ranarum)
Surgery/AmB (1week)+ itraconazole
(11 months); terbinafine 2 months
Cured
12/20 1996/2001 USA 46/M Abdominal pain,
abdominal mass
NR/NR/Yes I; Ce; appendix;
retroperitoneum
Histopathology/Culture
(B.ranarum)
Surgery/Itraconazole (19 months) Alive (31
months; 12
months after
itraconazole
withdrawal)
13/20 1998/2001 USA 52/M Abdominal pain 12,800 μL/14,3%/Yes C Histopathology/culture negative/
serology
Surgery/Itraconazole (10 months) Alive 4
months after
itraconazole
withdrawal)
14/20 1999/2001 USA 59/M Abdominal pain,
constipation
NR/NR/NR Ce; C Histopathology/Culture not done Surgery/Itraconazole (10 months) Alive
15/23 1999/2001 Kuwait
(Indian
patient)
41/M Fever, abdominal
pain, abdominal
mass
NR/NR/Yes Ce; C Histopathology/Culture from urine
(B.ranarum)/serology
Surgery/LAmB (4 weeks) Lost to
follow-up
16/24 2000/2003 Saudi Arabia 12/M Fever, abdominal
pain, abdominal
mass, scrotal
swelling
16,000 μL/15%/Yes I; Ce; C; L; BT Histopathology/Culture
(B.ranarum)
Surgery/Itraconazole (>24 months) Alive
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17/24 2001/2003 Saudi Arabia 12/M Fever, abdominal
pain
11,000 μL/20%/Yes I; Ce; C Histopathology Surgery/AmB than itraconazole (12
months)
Alive
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Table 2 (Continued)
Patient/Reference
Year observation/
Publication Country Age/sex
Clinical
presentation
Leukocyte/Eosinophils/Splendore-
Hoeppli phenomenon
Organ
involvement Diagnosis Therapy Outcome
18/24 2001/2003 Saudi Arabia 9/M Fever, abdominal
pain
17,800 μL/19.8%/NR Ce; C; R Histopathology/Culture
(B.ranarum)
Surgery/Itraconazole (10 months) Alive
19/24 2002/2003 Saudi Arabia 4/M Fever, abdominal
pain, hepatomegaly
30,000 μL/30%/NR L; intestine Histopathology/Culture
(B.ranarum) from liver biopsy
AmB than itraconazole (>12 months) Alive
20/24 2001/2003 Saudi Arabia 3/M Fever, abdominal
pain, heaptomegaly,
ascites
24,500μL/18%/Yes L Histopathology/Culture
(B.ranarum) from liver biopsy
AmB+5Flu Death of
MOF 2 days
after
admission
21/24 2000/2003 Saudi Arabia 7/M Fever, abdominal
pain, abdominal
distension,
hepatosplenomegaly
16,900 μL/17%/Yes R; D; BT Histopathology (liver biopsy) AmB + itraconazole (12 months) Death
(massive GI
bleeding)
22/25 NR/2003 Saudi Arabia 12/M Fever, abdominal
pain, anorexia,
weight loss,
vomiting,
constipation
17,900 μL/20%/Yes I; Ce; C Histopathology/Culture
(B.ranarum)
Surgery/Itraconazole (10 months) Alive
23/26 NR/2004 Iran 45/M Abdominal pain NR/NR/Yes Ce; L Histopathology Surgery/Ketoconazole + cotrimoxazole
(4 weeks)
Alive
24/27 NR/2004 Italy 40/F Fever, subcutaneous
lesions
28,320 μL/30%/Yes L; P; S; M; lung;
spleen; kidneys;
uterus
Post-mortem (histopathology) – Death due
shock and
pulmonary
failure
25/28 1990/2005 Brazil 43/M Fever, abdominal
pain, vomiting,
weight loss
10,800 μL/NR/Yes P Histopathology Surgery/ketoconazole (35 days) Follow-up
not stated
26/29 NR/2006 Iran 1.5/M Fever, abdominal
pain, diarrhea,
hematochezia
NR/Yes/Yes R Histopathology Surgery/AmB (1 week) than
itraconazole (9 months)
Alive
27/30 NR/2006 The
Netherlands
61/M Abdominal pain,
constipation
NR/27.7%/Yes C; L; gallbladder Histopathology; culture post-
mortem B.ranarum
Cholangiodrain/AmB Death due to
MOF few
days after
start
antifungal
therapy
28/31 NR/2007 Saudi Arabia 13/M Abdominal pain,
tenderness
NR/NR/Yes C Histopathology/Culture negative Surgery/Itraconazole Alive
29/32 2002-2007/2007 Iran 18/M Abdominal pain,
constipation
12,000 μL/8%/Yes I Histopathology Surgery/Itraconazole Alive (7
years)
30/32 2002-2007/2007 Iran 2.5/M Abdominal pain,
constipation, rectal
bleeding
26,800 μL/10%/Yes C Histopathology Surgery/Itraconazole Alive (10
years)
31/32 2002/2007 Iran 2/M Abdominal pain,
distension, ascites
29,400 μL/16%/Yes C Histopathology Surgery/Itraconazole Alive (7
years)
32/33 2000/2009 Saudi Arabia 77/M Abdominal pain,
abdominal mass,
weight loss, rectal
bleeding
Normal/NR/Yes Ce; C Histopathology Surgery/Itraconazole (2 weeks) Lost to
follow-up
33/33 2001/2009 Saudi Arabia 19/F Fever, abdominal
pain, weight loss
NR/NR/Yes Ce; C Histopathology/Culture (B.
ranarum)
LAmB + itraconazole; ketoconazole (4
years)
Alive (4
years)
34/33 NR/2009 Saudi Arabia 20/M Abdominal mass,
weight loss,
ematochezia
NR/NR/Yes C Histopathology/Culture (B.
ranarum)
Voriconazole Alive
35/34 NR/2011 Saudi Arabia 10/M Fever, abdominal
pain, vomiting
12,200 μL/17%/Yes Ce; Histopathology/PCR (B.ranarum) Itraconazole (12 months) Alive (1
year)
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Table 2 (Continued)
Patient/Reference
Year observation/
Publication Country Age/sex
Clinical
presentation
Leukocyte/Eosinophils/Splendore-
Hoeppli phenomenon
Organ
involvement Diagnosis Therapy Outcome
36/35 2003/2011 Saudi Arabia 6/M Fever, abdominal
pain, abdominal
mass
32,700 μL/11%/NR Ce; C; L Histopathology/Culture
(B.ranarum)
AmB than itraconazole Alive (2
years)
37/35 2003/2011 Saudi Arabia 13/F Fever, abdominal
pain
14,500 μL/18%/Yes I; Ce; C Histopathology Surgery/AmB + itraconazole (12
months)
Alive (2
years)
38/35 2003/2011 Saudi Arabia 8/F Fever, anorexia,
abdominal
distension, weight
loss
13,800 μL/4%/Yes P; L; BT Histopathology Surgery/AmB than itraconazole (18
months)
Alive 2,5
years)
39/36 NR/2011 Saudi Arabia 25/F Abdominal pain,
weight loss, nausea,
rectal bleeding
12,800 μL/NR/Yes C Histopathology Surgery/Itraconazole Alive
40/37 2010/2012 Saudi Arabia 2/M Fever, abdominal
pain, abdominal
mass, vomiting,
diarrhea
14,000 μL/19%/Yes I; Ce; C Histopathology AmB than voriconazole (12 months) Alive (1
year)
41/38 NR/2012 Iran 12/M Fever, abdominal
pain, vomiting,
bloody diarrhea
28,100 μL/16%/Yes C Histopathology Surgery/AmB (1 week) than
posaconazole
Follow-up
not stated
42/39 2008-2012/2012 Iran 1.3/F Abdominal pain,
distension
23,000 μL/17%/Yes S; C; M Histopathology/Culture negative Surgery/AmB than itraconazole Death due to
disseminated
disease
43/39 2008-2012/2012 Iran 5/M Abdominal pain,
weight loss
21,300 μL/20%/Yes C Histopathology/Culture negative Surgery/AmB than itraconazole Alive (8
months)
44/39 2008-2012/2012 Iran 5/M Abdominal pain 16,100 μL/10%/Yes C Histopathology/Culture negative Surgery/AmB than itraconazole Alive (3
years)
45/39 2008-2012/2012 Iran 2/M Abdominal pain,
diarrhea
17,400 μL/20%/Yes I; C Histopathology/Culture negative Surgery/AmB than itraconazole Alive (6
months)
46/39 2008-2012/2012 Iran 16/M Abdominal pain 11,500 μL/14%/Yes C Histopathology/Culture negative Surgery/AmB than itraconazole Alive (2
years)
47/39 2008-2012/2012 Iran 1.3/M Abdominal pain,
diarrhea
18,200 μL/8%/Yes S; I; C; M Histopathology/Culture negative Surgery/AmB than itraconazole Death due to
disseminated
disease (1,5
months)
48/39 2008-2012/2012 Iran 1.1/M Abdominal pain,
bloody stool
23,000 μL/16%/Yes C Histopathology/Culture negative Surgery/AmB than itraconazole Alive (1
year)
49/39 2008-2012/2012 Iran 37/M Abdominal pain 20,000 μL/10%/Yes C Histopathology/Culture negative Surgery/Itraconazole Alive (6
months)
50/39 2008-2012/2012 Iran 28/M Abdominal pain 14,000 μL/10%/Yes C Histopathology/Culture negative Surgery/Itraconazole Alive (2
years)
51/39 2008-2012/2012 Iran 52/M Abdominal pain,
vomiting, diarrhea
17,000 μL/15%/Yes C Histopathology/Culture negative Surgery/Itraconazole Alive (6
months)
52/39 2008-2012/2012 Iran 42/F Abdominal pain 17,000 μL/15.9%/Yes I; C Histopathology/Culture
(B.ranarum)
Surgery/Itraconazole Alive (1year)
53/40 NR/2013 USA 67/M Abdominal pain NR/NR/Yes I Histopathology/PCR (B.ranarum) Surgery/Ureteral stent/Fluconazole
(several months); posaconazole 600 (1
year)
Alive (2
years)
54/41 NR/2013 Saudi Arabia 4/M Fever, abdominal
pain, vomiting,
weight loss
17,000 μL/13.6%/Yes I; Ce; C Histopathology/Culture
(B.ranarum)
Surgery/Voriconazole (12 months) Alive (1
year)
55/42 NR/2013 Saudi Arabia 5/M Fever, abdominal
pain, bloody
diarrhea, anorexia,
weight loss
15,600 μL/15%/Yes C Histopathology/Culture negative Voriconazole (6 months) Alive (6
months)
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56/43 NR/2013 Iran 12/M Fever, abdominal
pain, hematuria
14,500 μL/No/Yes I; C Histopathology Surgery/Itraconazole + AmB (2 weeks)
then itraconazole
Death for
septic shock
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Table 2 (Continued)
Patient/Reference
Year observation/
Publication Country Age/sex
Clinical
presentation
Leukocyte/Eosinophils/Splendore-
Hoeppli phenomenon
Organ
involvement Diagnosis Therapy Outcome
57/44 2010/2013 Iraq 48/M Fever, abdominal
pain, weight loss
NR/12%/Yes Ce; C; L Histopathology Surgery/Itraconazole (6 months) Alive (1
year)
58/44 2010/2013 Iraq 1.5/M Fever, abdominal
pain, weight loss,
abdominal mass
NR/29%/Yes NR Histopathology AmB Death for
intestinal
perforation
59/44 2010/2013 Iraq 59/M Fever, abdominal
pain, weight loss,
abdominal mass
NR/No/Yes Ce Histopathology Surgery/Itraconazole (6 months) Alive (>1
year)
60/44 2012/2013 Iraq 53/M Fever, abdominal
pain, weight loss,
NR/NT/Yes Ce; C Histopathology Surgery/Itraconazole (6 months) Alive (10
months)
61/44 2012/2013 Iraq 39/M Fever, weight loss,
cough, sore throat
NR/9%/Yes O; C Histopathology Surgery/Itraconazole (7 months) Alive (7
months)
62/44 2012/2013 Iraq 1.5/M Fever, abdominal
pain, abdominal
mass, weight loss
NR/21%/Yes Ce; C Histopathology Surgery/Itraconazole (4 months) Alive (4
months)
63/45 NR/2013 Saudi Arabia 24/M Fever, abdominal
pain, weight loss,
diarrhea
14,400 μL/22%/NR I; Ce; C Histopathology/Culture
(B.ranarum)
Surgery/Itraconazole (12 months) Alive (1
year)
64/45 NR/2013 Saudi Arabia 21/F Fever, abdominal
pain, diarrhea
alternate with
constipation, weight
loss
7100 μL/No/NR Ce; C; R Histopahology/Culture (B.ranarum) Steroid/Itraconazole Death for
HC-
associated
infection
65/45 NR/2013 Saudi Arabia 72/M Fever, abdominal
mass
15,280 μL/No/NR Ce; C Histopahology/Culture (B.ranarum) Surgery/Itraconazole Death for
bowel
perforation
and ARDS,
septic shock
(32 days
post-surgery)
66/45 NR/2013 Saudi Arabia 19/M Fever, abdominal
pain, abdominal
mass
22,100 μL/6.65%/NR Ce; C Histopahology/Culture (B.ranarum) Surgery/Itraconazole Death for
HC-
associated
infection
67/46 2009-2012/2013 Saudi Arabia 12/F Fever, abdominal
pain, constipation
17,600μL/35%/Yes I; Ce Histopathology Surgery/Itraconazole Alive
68/46 2009-2012/2013 Saudi Arabia 1.5/M Fever,
hepatomegaly
24,520 μL/10.2%/Yes L Histopathology Surgery/Itraconazole Death for
ARDS after
few days
69/46 2009-2012/2013 Saudi Arabia 9/F Abdominal pain,
constipation,
vomiting
17,800 μL/14%/Yes C Histopathology Surgery/Itraconazole (8 months) Alive (8
months)
70/47 NR/2013 USA 34/F Abdominal pain,
constipation,
vomiting, weight
loss
13,000 μL/16.9%/NR I; Ce Histopahology/Culture (B.ranarum) Surgery/Itraconazole + LAmB (6
weeks)
Alive
71/48 NR/2013 Iran 3/M Abdominal pain,
abdominal mass
12,500 μL/6%/Yes C Histopahology/Culture (B.ranarum) Surgery/Posaconazole (3 months) then
itraconazole (12 months)
Alive (15
months)
72/49 2001/2014 Saudi Arabia 43/M Abdominal pain,
weight loss
15,000 μL/27%/Yes Ce; C; L Histopahology/Culture/(B.ranarum)
from liver
Surgery/Itraconazole (7 months) Alive (7
months)
73/49 2005/2014 Saudi Arabia 20/F Abdominal pain,
abdominal mass
NR/NR/NR C Histopahology/Culture (B.ranarum) Surgery Death
74/49 2008/2014 Saudi Arabia 63/M Abdominal pain,
weight loss
12,400 μL/14%/Yes I; C Histopathology/Culture negative Surgery/Voriconazole (12 months) Alive (12
months)
UNC
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75/49 2011/2014 Saudi Arabia 20/F Rectal bleeding 14,000 μL/20%/Yes R Histopathology Drainage/Terbinafine + voriconazole
(12 months)
Alive (12
months)
Table 2 (Continued)
Patient/Reference
Year observation/
Publication Country Age/sex
Clinical
presentation
Leukocyte/Eosinophils/Splendore-
Hoeppli phenomenon
Organ
involvement Diagnosis Therapy Outcome
76/50 2012/2014 Oman 5/F Abdominal pain,
nausea, vomiting,
low grade fever
14,200 μL/50%/Yes Ce, C Histopathology/Culture positive
(Basidiobolus spp.)
Surgery/LAmB + posaconazole then
voriconazole (4 months)
Alive (4
months)
77/51 2014 Mali/France 55/M Abdominal pain NR/NR/Yes I; C Histopathology/PCR (B. ranarum) Antituberculous treatment Death (2
months)
78/52 2012/2014 Iran 41/F Abdominal pain,
weight loss, nausea,
fever
14,300 μL/12%/Yes I; Ce; L Histopathology Surgery/Itraconazole (4 months) Alive (12
months)
79/53 2014 Saudi Arabia 11/M Abdominal pain NR/Yes/Yes C Histopathology Voriconazole (12 months) Alive (12
months after
discontinuing
therapy)
80/54 2014 Saudi Arabia 24/F Abdominal pain,
nausea, vomiting,
abdominal
distension,
constipation
7070 μL/14,6%/Yes L; C; P Histopathology/Culture & PCR
positive (B. ranarum)
Voriconazole Alive (2
months)
81/55 2014/2015 Saudi Arabia 36/M Suspected
appendicitis
16,000 μL/18%/Yes Ce Histopathology Surgery/Itraconazole (4 months);
voriconazole
Alive
82/56 /2015 USA
(Arizona)
56/M Abdominal pain,
rectal pain
NR/NR/NR Ce; R Histopathology Itraconazole (12 months) Alive (12
months)
83/57 2015 Iran 2/F Abdominal pain 11-12,000 μL/25–35%/Yes L Histopathology Surgery/AmB (1 month) Alive (9
months)
84/58 2015 Qatar 4/F Abdominal pain,
rectal bleeding,
weight loss,
NR/NR/Yes C Histopathology Surgery/Voriconazole (12 months) Alive (12
months)
85/59 NR/2016 India 44/M Liver transplant
patient; rise in
transaminases
NR/NR/NR L Culture (B. ranarum) of liver
aspirate
LAmB; itraconazole, caspofungin,
posaconazole
Death (MOF
and bacterial
sepsis)
86/60 NR/2017 Saudi Arabia 7/M Abdominal pain,
rectal bleeding,
weight loss, fever
10,030 μL/15.9%/Yes R Histopathology Surgery/Voriconazole (12 months) Alive (12
months)
87/61 NR/2017 Saudi Arabia 7/F Abdominal pain,
constipation, fever,
palpable mass
19,000μL(3000)/Yes C; R Histopathology Voriconazole (9 months) Alive (10
months)
88/62 NR/2017 Iran 5/M Abdominal pain,
fever, anorexia,
weight loss,
vomiting
23,900 μL/11%/Yes Ce; C; I Histopathology/Culture
(Basidiobolus spp.)
Amphotericin B (2 months);
posaconazole (6 months)
Alive (6
months)
89/PR 2013/2018 Italy/Ireland 25/M Abdominal pain 10,100 μL/10%/Yes I; Ce; C Histopathology/PCR (B.ranarum) Surgery/Itraconazole (8 months) Alive (13
months)
Twelve patients reported with no details in the review by Vikram et al. are not described in table. D, duodenum; E, esophagus; S, stomach; I, ileum; Ce, cecum; C, colon; R, rectum; O, oropharynx; BT, biliary tract; L, liver; P, peritoneum; M, mesentery; AmB,
amphotericin B; LAmB, liposomal amphotericin B.
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Table 3
Clinical manifestations, laboratory studies, sites of involvement and preliminary diagnosis
in 102 patients with gastrointestinal basidiobolomycosis.
Characteristic
Patients, proportion
(%) –Review by
Vikram (1964–2008)⁠21
Patients, proportion
(%)- Present review
(2009–2017) Total
Number of pts 44 (43.1%) 58 (56.9%) 102
Age, years,
median
37.3 (2–81) 17.5 (1.1–77) 19
(1.1–81)
Male sex 36 (81.8%) 40 (68.9%) 76
(74.5%)
Country of residence
Brazil 4 (9%) – 4 (3.9%)
Iran 4 (9%) 17 (29.3%) 21(20.6%)
Iraq – 6 (10.3%) 6 (5.9%)
Saudi Arabia 11 (25%) 27 (46.5%) 38
(37.2%)
USA 19 (43%) 3 (5.2%) 22
(21.6%)
Other 6 (13.6%) ⁠b 5 (8.6%) ⁠c 11
(10.8%)
Signs and symptoms
Abdominal pain 37 (84%) 51 (87.9%) 88
(86.3%)
Abdominal mass 19 (43%) 12 (20.7%) 31
(30.4%)
Constipation 17 (39%) 6 (10.3%) 23
(22.5%)
Abdominal
distension
14 (32%) 3 (5.2%) 17
(16.7%)
Fever 14 (32%) 27 (46.5%) 41
(40.2%)
Weight loss 12 (27%) 22 (37.9%) 34
(33.3%)
Diarrhea 7 (16%) 7 (12.1%) 14
(13.7%)
Vomiting 6 (14%) 10 (17.2%) 16
(15.7%)
Lower
gastrointestinal
bleeding
6 (14%) 9 (15.5%) 15
(14.7%)
Hepatomegaly 5 (11%) 1 (1.7%) 6 (5.9%)
Laboratory test results ⁠a
Peripheral blood
eosinophilia
26/34 (76%) 43/47 (91.5%) 69/81
(85.2%)
Positive
Basidiobolus
serology
8/16 (50%) – 8/16
(50%)
Growth of
Basidiobolus in
culture
17/24 (71%) 17/29 (58.6%) 34/53
(64.2%)
Characteristic
histopathology
43/44 (98%) 57/57 (100%) 100/101
(99%)
Organ involvement
Stomach 6 (14%) 2 (3.5%) 8 (7.9%)
Small bowel 16 (36%) 16 (28.1%) 32
(31.7%)
Colon/rectum 36 (82%) 50 (87.7%) 85
(84.2%)
Liver/gallbladder 13 (30%) 10 (17.5%) 22
(21.8%)
Pancreas – 3 (5.3%) 3 (2.9%)
Preliminary diagnosis
Malignancy 19 (43%) 6 (10.9%) 25
(24.7%)
Inflammatory
bowel disease
7 (16%) 6 (10.9%) 13
(12.9%)
Diverticulitis 5 (11%) – 5 (4.9%)
Appendicitis 3 (7%) 5 (9.1%) 8 (7.9%)
Lymphoma 2 (5%) 4 (7.3%) 6 (5.9%)
Gastrointestinal
tuberculosis
2 (5%) 3 (5.5%) 5 (4.9%)
Ameboma – 1 (1.8%) 1 (0.9%)
Schistosomiasis – 1 (1.8%) 1 (0.9%)
Other 4 (9%) – 4 (3.9%)
Antifungal
treatment
37/43 (86%) 56/58 (96.5%) 93/101
(92.1%)
Table 3 (Continued)
Characteristic
Patients, proportion
(%) –Review by
Vikram (1964–2008)⁠21
Patients, proportion
(%)- Present review
(2009–2017) Total
Itraconazole 26/37 (70.3%) 24/56 (42.9%) 50/93
(53.8%)
Amphotericin B 8/37 (21.6%) 2/56 (3.6%) 10/93
(10.7%)
Voriconazole 2/37 (5.4%) 10/56 (17.9%) ⁠d 12/93
(12.9%)
Posaconazole 0/37 (0%) 2/56 (3.6%) 2/93
(2.2%)
Amphotericin B
plus (or
followed by
azole)
3/37 (8.1%) 18/56 (32.1%) 21/93
(22.6%)
Outcome 8 (18%) died 11 (18.9%) died 19
(18.6%)
died
a Laboratory data are reported only when available.
b One patient each from:Nigeria, India, Bangladesh, Italy, The Netherlands; for 1
country was unknown.
c One patient each from: India, Ireland, Mali, Oman, Qatar.
d In one case associated with terbinafine.
the more frequently considered diagnosis (55.8%). In 32 cases (31.4%)
the diagnosis was obtained by histopathology plus culture and/or poly-
merase chain reaction (PCR), in 66 patients (64.7%) only by
histopathology. In four cases the correct diagnosis was achieved only
post-mortem. Overall, culture for B. ranarum was positive in 34/53 cases
(64.2%). Identification by PCR was obtained in 5 cases. Colon-rectum
were involved in 84.2% of cases. On histopathology the presence of fun-
gal hyphae, granulomatous inflammation, eosinophilic infiltration to-
gether with the Splendore-Höeppli phenomenon observed in the gas-
trointestinal tract should be considered highly suggestive for B. ranarum.
Overall 93/102 (91.2%) patients received an antifungal therapy Surgery
plus antifungal treatment was employed in 79/102 (77.5%) of patients.
Eleven patients received only antifungal treatment of which four died
(36.4%). Overall death was observed in 18.6% of patients.
4. Discussion
Basidiobolus ranarum is an environmental filamentous fungus that be-
longs to the phylum Entomophthoromycota, class Basidiobolomycetes
formerly designated as zygomycetes. Recent phylogenetic studies
showed that Entomophthromycota is a monophyletic lineage charac-
terised by coenocytic vegetative cells, sporulation by production of in-
fective conidia and production of zygospores capable of survival under
unfavourable environmental conditions. Basidiobolus spp. form uninu-
cleate cells with extremely large nuclei and had an haploid genome that
has been estimated to be 10 times larger (350Mb) than that of the av-
erage size of fungi [64]. The fungus grows at 30 °C in 2–3 days with
yellow-gray flat colonies but after 7–10 days colony become overgrown
with mycelia as masses of zygospores.
After its initial description by Eidam in 1886 [1], Basidiobolus ra-
narum was subsequently cultured from intestinal contents of frogs [65]
and several other species of amphibians and reptiles, from decaying
plant material, from an insectivorous bat (Rhinopoma hardwickei hard-
wickei) in India and from the faeces of kangaroos in Australia. The dis-
ease initially associated with B. ranarum was described in Indonesia
in 1956 by Joe et al. [9] as subcutaneous phycomycosis and subse-
quently the same presentation was identified in other areas of tropical
and subtropical climate, especially from Uganda, Nigeria and Indone-
sia. In 1964 the first case of gastrointestinal involvement was described
in a 6-year old Nigerian boy at postmortem examination [4]. Gastroin-
testinal basidiobolomycosis (GIB) has been considered an extremely rare
disease with only six cases reported up to 1999 [63]. Within the past 2
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Fig. 4. Geographical distribution of cases of 101 gastrointestinal basidiobolomycosis reported worldwide (for one case the country was unknown).
decades a 15-fold increase in cases of gastrointestinal infection by B. ra-
narum has been reported worldwide. Although most of the cases have
been described in the Middle East (Saudi Arabia, Iran, Iraq, Kuwait,
Oman, Qatar) [23–26,29,31–39,41–46,48–50,52–55,57,60,62] and the
southwestern of United States (Arizona and Utah) [15,17–20,40,47,56],
sporadic reports came from South America, Africa, Europe and the In-
dian Subcontinent [4,12,14,16,27,28,30,51, 59,PR] and no clear envi-
ronmental risk factors have been identified. In the case-control study
performed by Lyon et al. in Arizona, ranitidine use (OR 6.0) and a
longer period of smoking (OR 2.1/additional 20 years of smoking) were
both associated with the development of the disease [20]. It has been
hypothesized that the decreased gastric acidity together with the alter-
ation of white blood cells activity induced by smoking might contribute
to the survival of ingested B. ranarum. However, rural environment and
activities such as gardening and landscaping as well as ingestion of con-
taminated soil or fruits and vegetables seem to be associated with a
higher risk of exposure to the infection [21]. Since B. ranarum usually
involves immunocompetent subjects, factors associated with health his-
tory of the hosts are not helpful for the diagnosis that is therefore fre-
quently delayed. Of the three patients reported in Europe [27,30, PR],
only the one described here was diagnosed during life. However, at least
in endemic areas, a higher awareness of GIB by clinicians might par-
tially account for the increase in the number of cases reported in the last
decades. As in previous cases, in our patient the route of acquisition of
the disease remains unknown; however since B. ranarum can be found
in soil and decaying vegetables, we hypothesized that the consumption
of homebrew unpasteurized and unfiltered beer might have been the
source of fungal ingestion and subsequent involvement of the intestine.
A preliminary misdiagnosis among patients with GIB was commonly
reported in the literature, the most frequent being gastrointestinal ma-
lignancy and inflammatory bowel diseases
[17,22,30,33,34,36,37,41,42,56,61,62, PR], although a suspicion
should be raised whenever fever and abdominal pain occur in young pa-
tients with gastrointestinal, abdominal mass or intestinal wall thicken-
ing in association with high eosinophilia.
Although a definite diagnosis can be obtained with culture
[14,15,18,19,22–24,30,33,35,41,45,47,49–51,54,59,62], it was fre-
quently missed in previous reports because of the lack of suspicion that
made tissue specimens unavailable for culture purpose. Therefore, the
diagnosis of gastrointestinal infection by B. ranarum was mainly ob-
tained on histologic examination, which typical morphologic features
include granulomatous inflammation and a diffuse eosinophilic infil-
trate with thin walled branched hyphae surrounded by eosinophilic
material (Splendore-Höeppli phenomenon) and sometimes zygospores
(spherical bodies with foamy cytoplasm)
[4,6,12,16,17,20,24,26–29,31–33,35–39,42–44,46,49,52,53,55,58,60,61].
The immunodiagnostic test such as immunodiffusion is not standardized
yet, since it showed a high specificity but a controversial sensitivity
[20]. Finally, since suitable specimens for culture purpose are often un-
available, molecular diagnosis from formalin fixed paraffin embedded
tissue represents the optimal adjunctive diagnostic method to histology,
as it showed a high specificity and high sensitivity [34,40,51,54,PR].
Treatment of GIB usually requires a combination of surgical and
medical approach. Surgical resection of infected bowel tissues must be
followed by itraconazole for at least 6 months to prevent recurrence.
There are also a few cases described in the literature that showed a suc-
cessful outcome with antifungal treatment alone [33–35,42,56,61]. The
role of amphotericin B has been overcome since resistance has been ob-
served in more than 50% of cases [25]. Potassium iodide (KI) has been
traditionally used for the treatment of subcutaneous basidiobolomycosis
and more recently it was employed successfully in a single case report
of a child with GIB [21,66,67]. However, as suggested by Bering et al.,
the absence of demonstrable in vitro activity of KI against B. ranarum
coupled with several possible limitations (toxicity associated with high
doses, lack of any standard prescription recommendation, available new
azoles) do not recommend its use in GIB [68]. More recently successful
treatments with voriconazole [42,49,50,53–55,58,59] and posaconazole
[40,48,50] have been reported. On the basis of the experience reported
in the literature azoles should be considered the drugs of choice for GIB.
5. Conclusions
In conclusion, GIB should be suspected in patients complaining ab-
dominal pain associated with gastrointestinal and/or colon mass who
has concomitant peripheral eosinophilia especially if they come from
the Middle-East or arid zone from USA. Moreover, the observation of
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the Splendore-Höeppli phenomenon (although not pathognomonic be-
ing associated with several microorganisms) [69] in the presence of
zygomicetes in tissue samples from immunocompetent patients should
raise the suspicion of basidiobolomycosis and confirmation by using
molecular diagnosis should be sought through pathologists able to do it.
Although some reports indicate successful outcome by using only med-
ical therapy, surgery with resection of affected bowel segments associ-
ated with prolonged antifungal treatment should be advised. Itracona-
zole seems to be the best available treatment although other new azoles
have also been successfully employed. The exact length of duration of
antifungal therapy remains to be established.
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